がん骨転移治療

出版社: 先端医学社
著者:
発行日: 2012-03-30
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784884077983
電子書籍版: 2012-03-30 (第1版第3刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,060 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,530 円(税込)

商品紹介

骨転移は、近年のがん治療の進歩による予後延長などに伴い、珍しい疾患ではなくなりつつある。本書では、骨転移の集学的治療を中心に、これまでの手術療法,放射線療法、オピオイドによる除痛に、ビスホスホネート治療を加えた包括的な骨の管理「Bone Management」について、各分野の第一人者が解説。骨転移の病態/基本的治療、診断方法、がん種別などの各項目に加え、Q&Aも充実したがん治療にかかわる医療者必携の実践書となっている。

目次

  • がん骨転移治療

    ―目次―

    Part 1 骨転移治療概論
        ―Bone Management の意義を中心に―
     1. がん治療における骨の管理の重要性
     2. 骨転移治療の現況と臨床的課題を探る
     3. 骨転移成立・進展のメカニズムはどこまで解明されたのか

    Part 2 Bone Management の観点から骨転移BP治療の
        臨床的意義を探る
     1. 総論 骨転移治療においてBP 治療を実施する
           メリットとは何か?
     2. BP 製剤の薬理プロファイルから期待される骨強度改善
       (骨質の観点を中心に)
     3. BP 製剤の薬理プロファイルから期待される
        骨転移進行抑制と疼痛緩和
     4. がん治療誘発性骨量減少に対するBP 治療
        ―骨の脆弱化を防ぐために―
     5. 骨転移高リスク患者へのBP 治療の可能性
        ―スクリーニングと早期介入の意義―
     6. BP 治療による骨関連事象(SRE)の抑制とQOL の維持
     7. 悪性腫瘍に伴う高Ca 血症へのBP 治療の有益性
     8. 医療経済からみたBP 治療の有益性

    Part 3 骨転移診断の基本を理解する
     1. 骨転移にみられる特徴的な症状や痛み,
        骨関連事象(SRE)を知る
     2. 骨転移が疑われた際の診察・問診の進め方と早期発見の
        ポイントをみる
     3. 骨転移が疑われた際の基本的な検査と画像診断をみる
        ―骨転移の画像診断―

    Part 4 骨転移治療の実際をみる
     1. 治療法の種類と予後予測に基づく
        基本的な治療方針の考え方をみる
     2. BP 治療の適応と投与の実際をみる
     3. 放射線療法を中心とした治療とその実際をみる
        ―放射線科の立場から―
     4. 外科的介入を中心とした治療とその実際をみる
        ―整形外科の立場から―
     5. 集学的治療の実際をみる

    Part 5 がん種別骨転移治療の実際をみる
     1. 乳がん骨転移に対する治療の実際をみる
     2. 泌尿器がん骨転移に対する治療の実際をみる
        (前立腺がん・腎がん)
     3. 肺がん骨転移に対する治療の実際をみる
     4. 消化器がん骨転移に対する治療の実際をみる
     5. 造血器悪性腫瘍における骨病変に対する治療の実際をみる
     6. 原発不明がん骨転移に対する治療の実際をみる

    Part 6 骨転移におけるBP 治療の副作用対策をみる
     1. BP 治療に関連する腎障害とそのコントロールは
        いかにおこなうか
     2. BP 関連顎骨壊死とその対応をみる

    Part 7 骨転移治療の今後を展望する
     1. 骨転移治療の将来展望とBP 治療の可能性を探る
        ―BP の抗腫瘍効果―
     2. 新規治療薬の開発と臨床応用の可能性を探る
        ―抗RANKL 抗体などを中心に―

    Part 8 骨転移治療 advanced lecture Q&A
     Q1 痛みのない骨転移患者に対するBP 治療の意義について
        教えてください
     Q2 骨転移,画像診断時の鑑別上の注意点について
        教えてください
     Q3 骨転移治療の装具療法について教えてください
     Q4 ストロンチウムとBP 治療の併用の実際について
        教えてください
     Q5 造骨型,溶骨型のタイプの違いによりBP 治療の効果は
        異なるのでしょうか
     Q6 骨転移痛に対する神経ブロックの適応について
        教えてください
     Q7 骨転移治療における骨代謝マーカー測定の意義について
        教えてください

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 骨転移治療概論 - Bone Managementの意義を中心に -

P.20 掲載の参考文献
P.26 掲載の参考文献
3) Hillner BE, Ingle JN, Chlebowski RT et al:American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
6) Fleisch H:Bisphosphonate in Bone Disease, Third Edition:From the Laboratory to the Patient, The Parthenon Publishing Group, New York, 1997
9) Yoneda T, Hagino H, Sugimoto T et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010
10) Morgan GJ, Davies FE, Gregory WM et al:First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controlled trial. Lancet 376:1989-1999, 2010
11) Gnant M, Mlineritsch B, Schippinger W et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
12) Coleman RE, Marshall H, Cameron D et al:Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
13) Lipton A, Goessl C:Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48:96-99, 2011
14) Saad F, Lipton A:SRC kinase inhibition:targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36:177-184, 2010
15) Saylor PJ, Lee RJ, Smith MR:Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29:3705-3714, 2011
P.32 掲載の参考文献
2) Paget S:The distribution of secondary growths in cancer of the breast. Lancet i:571-573, 1889
3) Yoneda T, Sasaki A, Mundy GR:Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73-84, 1994
4) Sela J:Bone remodeling in pathological conditions. Calcif Tiss Res 23:229-234, 1977
5) Boyde A, Maconnachie E, Reid SA et al:Scanning electron microscopy in bone pathology:review of methods, potential and applications. Scan Electron Microsc 4:1537-1554, 1986
7) Hauschka PV, Mavrakos AE, Iafrati MD et al:Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261:12665-12674, 1986
9) Kearns AE, Khosla S, Kostenuik PJ:Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155-192, 2008
11) Hiraga T, Myoui A, Choi ME et al:Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 66:2067-2073, 2006
12) Hiraga T, Kizaka-Kondoh S, Hirota K et al:Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67:4157-4163, 2007
13) Weilbaecher KN, Guise TA, McCauley LK:Cancer to bone:a fatal attraction. Nat Rev Cancer 11:411-425, 2011
14) Yoneda T, Williams PJ, Hiraga T et al:A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner, Res 16:1486-1495, 2001
15) Scheel C, Weinberg RA:Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129:2310-2314, 2011
17) Schulman KL, Kohles J:Economic burden of metastatic bone disease in the U.S. Cancer 109:2334-2342, 2007
18) Vallet S, Smith MR, Raje N:Novel bone-targeted strategies in oncology. Clin Cancer Res 16:4084-4093, 2010

Part 2 Bone Managementの観点から骨転移BP治療の臨床的意義を探る

P.41 掲載の参考文献
1) Hortobagyi GM, Theriault RL, Lipton A et al:Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998
2) Theriault RL, Lipton A, Hortobagyi GM et al:Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999
3) Kohno N, Aogi K, Minami H et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
4) Rosen LS, Gordon DH, Dugan W Jr et al:Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43, 2004
5) Saad F, Gleason DM, Murray R et al:Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004
6) Rosen LS, Gorden D, Tchekmedyian NS et al:Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621, 2004
7) Clemons MJ, Dranitsaris G, Ooi WS et al:Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24:4895-4900, 2006
8) Paterson AH, Powles TJ, Kanis JA et al:Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
9) Body JJ, Diel IJ, Lichinitzer M et al:Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease:results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133-1137, 2004
10) Morgan GJ, Davies FE, Gregory WM et al:First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controlled trial. Lancet 376:1989-1999, 2010
11) Green JR:Antitumor effects of bisphosphonates. Cancer 97(3 Suppl):840-847, 2003
12) Mundy GR:Metastasis to bone:causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2004
13) Dieli F, Gebbia N, Poccia F et al:Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310-2311, 2003
14) Tanaka Y:Human γδT cells and tumor immuno-therapy. J Clin Exp Hematopathol 46:11-23, 2006
15) Ullen A, Lennartsson L, Harmenberg U et al:Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 44:644-650, 2005
16) Ottewell PD, Monkkonen H, Jones M et al:Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178, 2008
17) Gnant M, Mlineritsch B. Schippinger W et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
18) Coleman RE, Winter MC, Cameron D et al:The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumor response:exploratory evidence for direct anti-tumor activity in breast cancer. Br J Cancer 102:1099-1105, 2010
19) Hiraga T, Williams PJ, Ueda A at al:Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567, 2004
20) Braun S, Vogl FD, Naume B et al:A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005
21) Bidard FC, Salomon AV, Gomme S et al:Disseminated tumor cells of breast cancer patients:a strong prognostic factor for distant and local relapse. Clin Cancer Res 14:3306-3311, 2008
22) Lin A, Park J, Melisko M et al:Zoledronic acid as adjuvant therapy for women with early stage breast cancer cells and occult tumor cells in bone marrow. Cancer Res 68:510, 2007(abstr)
23) Rack B, Schindelbeck C, Strobl B et al:[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. Dtsch Med Wochenschr 133:285-289, 2008
24) Aft R, Naughton M, Trinkaus K et al:Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer:an open label, randomised, phase 2 trial. Lancet oncol 11:421-428, 2010
25) Mystakidou K, Katsouda E, Parpa E et al:Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med oncol 22:195-201, 2005
P.48 掲載の参考文献
1) Rogers MJ, Frith JC, Luckman SP et al:Molecular mechanisms of action of bisphosphonates. Bone 24:73S-79S, 1999
2) Black DM, Cummings SR, Karpf DB et al:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996
3) Harris ST, Watts NB, Genant HK et al:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:arandomized controlled trial. Vertebral Efficacy With Risedronate Therapy(VERT)Study Group. JAMA 282:1344-1352, 1999
4) Mori H, Tanaka M, Kayasuga R et al:Minodronic acid(ONO-5920/YM529)prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:840-848, 2008
5) Recker R, Masarachia P, Santora A et al:Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21:185-194, 2005
6) Imai K, Ohnishi I, Matsumoto T et al:Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801-810, 2009
7) Roschger P, Rinnerthaler S, Yates J et al:Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191, 2001
8) Seeman E:Periosteal bone formation--a neglected determinant of bone strength. N Engl J Med 349:320-323, 2003
9) Greenspan SL, Beck TJ, Resnick NM et al:Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry:a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 20:1525-1532, 2005
10) Bonnick SL, Beck TJ, Cosman F et al:DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911-921, 2009
11) Mayhew PM, Thomas CD, Clement JG et al:Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet 366:129-135, 2005
12) Nuzzo S, Lafage-Proust MH, Martin-Badosa E et al:Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens:effects of etidronate treatment. J Bone Miner Res 17:1372-1382, 2002
13) Boivin GY, Chavassieux PM, Santora AC et al:Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694, 2000
14) Saito M, Mori S, Mashiba T:Long-term treatment of incadronate increases degree of mineralization, collagen maturity, and non-enzymatic collagen crosslink, pentosidine, in dog rib. Transactions of ORS 32:1312, 2007
P.54 掲載の参考文献
2) Brown JE, Cook RJ, Major P et al:Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
3) Weilbaecher KN, Guise TA, McCauley LK:Cancer to bone:a fatal attraction. Nat Rev Cancer 11:411-425, 2011
4) Coleman R, Cook R, Hirsh V et al:Zoledronic acid use in cancer patients:more than just supportive care? Cancer 117:11-23, 2011
5) Giraudo E, Inoue M, Hanahan D:An amino-bisphos-phonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633, 2004
6) Santini D, Vincenzi B, Galluzzo S et al:Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482-4486, 2007
7) Kunzmann V, Bauer E, Wilhelm M:γ/δ T-cell stimulation by pamidronate. N Engl J Med 340:737-738, 1999
8) Roelofs AJ, Jauhiainen M, Monkkonen H et al:Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245-250, 2009
9) Sato K, Kimura S, Segawa H et al:Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116:94-99, 2005
10) Santini D, Martini F, Fratto ME et al:In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31-38, 2009
11) Hiraga T, Williams PJ, Ueda A et al:Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567, 2004
12) Gnant M, Mlineritsch B, Schippinger W et al:Endo-crine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
13) Coleman RE, Marshall H, Cameron D et al:Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
16) Mantyh PW, Clohisy DR, Koltzenburg M et al:Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201-209, 2002
17) Nagae M, Hiraga T, Yoneda T:Acidic micro-environment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99-104, 2007
18) Nakanishi M, Hata K, Nagayama T et al:Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade:a potential mechanism of inflammatory pain. Mol Biol Cell 21:2568-2577, 2010
19) Yoneda T, Hata K, Nakanishi M et al:Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48:100-105, 2011
P.59 掲載の参考文献
1) 木村将貴, 佐藤威文, 岡崎美代子ほか:前立腺癌のアンドロゲン除去療法におけるビスフォスフォネートの臨床的意義:リセドロネートの検討. 日泌会誌 99:22-28, 2008
2) Shahinian VB, Kuo YF, Freeman JL et al:Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
3) 高橋俊二:骨粗鬆症の病態と診断, その対策. 綜合臨床 59:568-572, 2010
4) 骨粗鬆症の予防と治療ガイドライン作成委員会編:骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 東京, 2006
5) Yamamoto M, Yamaguchi T, Yamauchi M et al:Low serum level of the endogenous secretory receptor for advanced glycation end products(esRAGE)is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 32:2263-2268, 2009
7) Black DM, Delmas PD, Eastell R et al:Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822, 2007
8) Satoh T, Kimura M, Matsumoto K et al:Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468-3474, 2009
9) 米田俊之, 萩野浩, 杉本利嗣ほか:ビスフォスフォネート関連顎骨壊死に対するポジションペーパー. 日歯周誌 52:265-269, 2010
10) Saad F, Brown JE, Van Poznak C et al:Incidence, risk factors, and outcomes of osteonecrosis of the jaw:integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol, 2011(in press)
11) Ellsworth P, Carithers G, DiPaolo R et al:Educational needs of urologists on bone health in prostate cancer. American Urological Association Annual Meeting 2011:#722, 2011(abstr)
12) Bliuc D, Nguyen ND, Milch VE et al:Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521, 2009
P.66 掲載の参考文献
1) Scheid V, Buzdar AU, Smith TL et al:Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58:2589-2593, 1986
3) Van Poznak CH, Temin S, Yee GC et al:American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
5) Rennert G, Pinchev M, Rennert HS:Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581, 2010
6) Newcomb PA, Trentham-Dietz A, Hampton JM:Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802, 2010
7) Stresing V, Daubin F, Benzaid I et al:Bisphosphonates in cancer therapy. Cancer letters 257:16-35, 2007
8) Diel IJ, Jaschke A, Solomayer EF et al:Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow:a long-term follow-up. Ann Oncol 19:2007-2011, 2008
9) Powles T, Paterson A, McCloskey E et al:Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer[ISRCTN83688026]. Breast Cancer Res 8:1-7, 2006
10) Saarto T, Vehmanen L, Virkkunen P et al:Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004
11) Paterson AGH, Anderson SJ, Lembersky BC et al:NSABP protocol B-34:a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. SABCS 2011:S2-3, 2011(abstr)
12) Kristensen B, Ejlertsen B, Mouridsen HT et al:Bisphosphonate treatment in primary breast cancer:results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740-746, 2008
13) Brufsky AM, Bosserman LD, Caradonna RR et al:Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole:Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
14) Eidtman H, DeBoer R, Bundred N et al:Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
15) DeBoer R, Bundred N, Eidtman H et al:The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole:the ZOFAST study 5-year final follow-up. SABCS 2010:P5-11-01, 2010(abstr)
16) Gnant M, Mlineritsch B, Schippinger W et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
17) Gnant M, Mlineritsch B, Stoeger H et al:Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
18) Coleman RE, Marchell H, Cameron D et al:Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
19) Coleman RE, Winter MC, Cameron D et al:The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response:exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105, 2010
P.74 掲載の参考文献
1) Harrington KD, Johnston JO, Turner RH et al:The use of methylmethacrylate as an adjunct in the internal fixation of malignant neoplastic fractures. J Bone Joint Surg Am 54:1665-1676, 1972
3) Harada H, Katagiri H, Kamata M et al:Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res(Tokyo) 51:131-136, 2010
4) Yazawa Y, Frassica FJ, Chao EY et al:Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 251:213-219, 1990
5) Taneichi H, Kaneda K, Takeda N et al:Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine 22:239-245, 1997
6) 浜名俊彰, 高橋満, 宮城憲文ほか:転移性上位胸椎腫瘍における単純X線正面像の評価. 臨整外 34:27-32, 1999
7) Rades D, Stalpers LJ, Veninga T et al:Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 23:3366-3375, 2005
8) Katagiri H, Takahashi M, Inagaki J et al:Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys 42:1127-1132, 1998
9) Kohno N, Aogi K, Minami H et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
10) Saad F, Gleason DM, Murray R et al:Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004
11) Saad F, Chen YM, Gleason DM et al:Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5:390-396, 2007
12) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
13) Durie BG, Katz M, Crowley J:Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102, 2005
14) Ishizuna K, Ota D, Fukuuchi A et al:A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid. Breast Cancer, 2011(ahead of print)
P.79 掲載の参考文献
1) Mundy GR, Martin TJ:The hypercalcemia of malig-nancy:pathogenesis and management. Metabolism 31:1247-1277, 1982
3) Inoue D, Matsumoto T:Parathyroid hormone-related peptide and bone:pathological and physiological aspects. Biomed Pharmacother 54(Suppl 1):32s-41s, 2000
4) Major P, Lortholary A, Hon J et al:Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567, 2001
P.84 掲載の参考文献
1) Body JJ:Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97:859-865, 2003
2) Botteman M, Barghout V, Stephens J et al:Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 17:1072-1082, 2006
3) Hillner BE, Weeks JC, Desch CE et al:Pamidronate in prevention of bone complications in metastatic breast cancer:a cost-effectiveness analysis. J Clin Oncol 18:72-79, 2000
4) Reed SD, Radeva JI, Glendenning GA et al:Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 171:1537-1542, 2004
5) Xie J, Namjoshi M, Wu EQ et al:Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 17:621-643, 2011

Part 3 骨転移診断の基本を理解する

P.90 掲載の参考文献
1) Costa L, Major PP:Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163-174, 2009
2) Onishi T, Hayashi N, Theriault RL et al:Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7:641-651, 2010
3) Sturge J, Caley MP, Waxman J:Bone metastasis in prostate cancer:emerging therapeutic strategies. Nat Rev Clin Oncol 8:357-368, 2011
4) Weilbaecher KN, Guise TA, McCauley LK:Cancer to bone:a fatal attraction. Nat Rev Cancer 11:411-425, 2011
5) Kohno N, Aogi K, Minami H et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
8) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
9) Yuasa T, Kimura S, Ashihara E et al:Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 14:2126-2135, 2007
10) Jimenez-Andrade JM, Mantyh WG, Bloom AP et al:Bone cancer pain. Ann NY Acad Sci 1198:173-181, 2010
11) Clines GA, Guise TA:Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12:549-583, 2005
13) Oefelein MG, Ricchiuti V, Conrad W et al:Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007, 2002
14) Higano CS:Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer:what do we really know? Nat Clin Pract Urol 5:24-34, 2008
15) Wang W, Yuasa T, Tsuchiya N et al:Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 15:943-952, 2008
16) Yuasa T, Maita S, Tsuchiya N et al:Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75:1131-1137, 2010
17) Shoskes DA, Perrin RG:The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol 142:337-339, 1989
18) Ed by Kantoff P, Saad F, Smith MR:Management of skeletal complications of prostate cancer and other genitourinary malignancies, F.A.Davis, Philadelphia, 2004
19) 泌尿器科がん骨転移に対する治療法のupdate. 日本泌尿器科学会 卒後・生涯教育テキスト, 篠原信雄, 湯浅健, 大坂康博編, 日本泌尿器科学会, 東京, 2007
20) Ratanatharathorn V, Powers WE, Moss WT et al:Bone metastasis:review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 44:1-18, 1999
21) Finlay PG, Mason PD, Shelley D:Radioisotopes for the palliation of metastatic bone cancer:a systematic review. Lancet Oncol 6:392-400, 2005
22) Bickels J, Dadia S, Lidar Z:Surgical management of metastatic bone disease. J Bone Joint Surg Am 91:1503-1516, 2009
23) Wise JJ, Fischgrund JS, Herkowitz HN et al:Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine(Phila Pa 1976) 24:1943-1951, 1976
24) Patchell RA, Tibbs PA, Regine WF et al:Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer:a randomised trial. Lancet 366:643-648, 2005
P.95 掲載の参考文献
1) Galasko C:The anatomy and pathways of skeletal metastases. In:Bone metastases, ed by Weiss L, Gilbert A, GK Hall, Boston, 1981, pp.49-63
2) Koizumi M, Yoshimoto M, Kasumi F et al:An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer 10:381, 2010
3) Coleman R, Rubens R:The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
4) Fang K, Peng C:Predicting the probability of bone metastasis through histological grading of prostate carcinoma:a retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimen. J Urol 130:708-711, 1983
5) Front D, Schenk SO, Frankel A et al:Bone metastases and bone pain in breast cancer. Are they closely associated? JAMA 242:1747-1748, 1979
6) Nachemson AL:Neck and Back Pain. In:The scientific evidence of cause, diagnosis and treatment, ed by Jonsson E, Lippincott, Williams & Wilkins, Philadelphia, 2000, p192
7) Mirels H:Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Res 249:256-264, 1989
8) Damron TA, Morgan H, Prakash D et al:Critical evaluation of Mirels' rating system for impending pathologic fractures. Clin Orthop Relat Res 415(suppl):s201-s207, 2003
9) Costelloe CM, Rohren EM, Madewell JE et al:Imaging bone metastases in breast cancer:techniques and recommendations for diagnosis. Lancet Oncol 10:606-614, 2009
10) Rosseli Del Turco M, Palli D, Cariddi A et al:Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 27:1593-1597, 1994
11) The GIVIO Investigators:Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587-1592, 1994
12) Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 15:2149-2156, 1997
P.111 掲載の参考文献
1) Resnick D:Skeletal metastasis(Chapter 78). In:Diagnosis of bone and joint disorders 4th ed, ed by Donald Resnick, Saunders, Philidelphia, 2002
2) Koizumi M, Yoshimoto M, Kasumi F et al:Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 14:1234-1240, 2003
4) Koizumi M, Yoshimoto M, Kasumi F et al:An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC cancer 10:381, 2010
5) Koyama M, Koizumi M:Two cases of diffuse osteoblastic metastases from early type gastric cancer. Clin Nucl Med 32:545-547, 2007
6) 遠藤啓吾編, 小泉満著:全身骨転移を探る-骨シンチグラフィ, メディカルチャー, 東京, 2000

Part 4 骨転移治療の実際をみる

P.120 掲載の参考文献
1) Katagiri H, Takahashi M, Wakai K et al:Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698-703, 2005
2) 徳橋泰明, 松崎浩巳, 小田博ほか:骨転移の診断と最新治療【治療】外科的治療 転移性骨腫瘍の手術適応と予後予測. 骨・関節・靭帯 17:452-459, 2004
3) 徳橋泰明, 松崎浩巳, 根本泰寛ほか:脊椎転移癌に対する術式選択とその治療成績-術前予後判定点数による治療戦略. 臨整外 38:739-745, 2003
5) Oken MM, Creech RH, Tormey DC et al:Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
6) Yazawa Y, Frassica FJ, Chao EY et al:Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop 251:213-219, 1990
8) Van der Linden YM, Dijkstra PD, Kroon HM et al:Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 86:566-573, 2004
9) Menck H, Schulze S, Larsen E:Metastasis size in pathologic femoral fractures. Acta Orthop Scand 59:151-154, 1988
10) Dijkstra PD, Oudkerk M, Wiggers T:Prediction of pathological subtrochanteric fractures due to metastatic lesions. Arch Orthop Trauma Surg 116:221-224, 1997
11) 杉浦英志:悪性腫瘍とリハビリテーション. 3. 骨転移と運動負荷. MB Med Reha 60:15-21, 2005
12) 杉浦英志, 山田健志, 小澤英史ほか:転移性骨腫瘍に対するビスフォスフォネート療法. 関節外科 26:47-52, 2007
13) 杉浦英志, 山田健志, 和佐潤志ほか:肺癌骨転移における外科的治療の適応. 日整会誌 79:549-554, 2005
14) 鈴木喜貴, 杉浦英志, 山田健志ほか:四肢長管骨骨幹部転移性骨腫瘍に対すアドリアマイシン混入セメントを併用した髄内釘による治療. 臨整外 39:79-83, 2004
15) 中島浩敦, 筑紫聡, 紫藤洋二ほか:大腿骨近位転移性骨腫瘍に対する腫瘍切除・人工骨頭置換術の治療経験. 関節外科 23:129-133, 2004
16) 和佐潤志, 杉浦英志, 山田健志:転移性腫瘍による病的骨折の治療 転移性腫瘍による上肢病的骨折の治療. 日整会誌 81:335-339, 2007
17) Taneichi H, Kaneda K, Takeda N et al:Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine(Phila Pa 1976) 22:239-245, 1997
18) 高橋満, 片桐浩久, 高木辰哉ほか:脊椎転移癌に対する治療法の選択:転移性脊椎腫瘍に対する放射線治療の適応とその成績. 関節外科 22:1029-1036, 2003
19) 片桐浩久, 高橋満, 杉浦英志ほか:脊椎骨への癌転移非手術的治療の成績と治療方針. 現代医学 46:41-50, 1998
20) Patchell RA, Tibbs PA, Regine WF et al:Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer:a randomised trial. Lancet 366:643-648, 2005
21) Loblaw DA, Laperriere NJ:Emergency treatment of malignant extradural spinal cord compression:an evidence-based guideline. J Clin Oncol 16:1613-1624, 1998
P.126 掲載の参考文献
2) Van Poznak CH, Temin S, Yee GC et al:American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
3) Bounameaux HM, Schifferli J, Montani JP et al:Renal failure associated with intravenous diphosphonates. Lancet i(8322):471, 1983
4) Dieli F, Gebbia N, Poccia F et al:Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310-2311, 2003
5) Christodoulou C, Pervena A, Klouvas G et al:Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209-211, 2009
P.131 掲載の参考文献
1) Chow E, Harris K, Fan G et al:Palliative radio-therapy trials for bone metastases:a systematic review. J Clin Oncol 25:1423-1436, 2007
2) Lutz S, Berk L, Chang E et al:Palliative radio-therapy for bone metastases:an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965-976, 2011
3) Souchon R, Wenz F, Sedlmayer F et al:DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer:bone metastases and metastatic spinal cord compression(MSCC). Strahlenther Onkol 185:417-424, 2009
4) 高橋健夫:転移性腫瘍における放射線療法 骨転移. 大西洋, 唐澤久美子, 唐澤克之編:がん・放射線療法 2010. 篠原出版新社, 東京, 2010, pp.1187-1195
5) Takahashi T, Hondo M, Nishimura K et al:Evaluation of quality of life and psychological response in cancer patients treated with radiotherapy. Radiat Med 26:396-401, 2008
6) Roos DE, Turner SL, O'Brien PC et al:Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases(Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 75:54-63, 2005
7) Mizumoto M, Harada H, Asakura H et al:Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column:a review of 544 patients at Shizuoka Cancer Center Hospital. Cancer 113:2816-2822, 2008
8) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain:randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52:111-121, 1999
9) Kaasa S, Brenne E, Lund JA et al:Prospective randomised multicenter trial on single fraction radiotherapy(8 Gy x 1)versus multiple fractions(3 Gy x 10)in the treatment of painful bone metastases. Radiother Oncol 79:278-284, 2006
10) Wu JS, Wong R, Johnston M et al:Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594-605, 2003
11) Hoskin PJ:Radiotherapy in symptom management. In:Oxford Textbook of Palliative Medicine, 3rd edition, ed by Doyle D, Hanks G, Cherny N et al, Oxford University Press. New York, 2004, pp.239-255
12) Roos DE, O'Brien PC, Smith JG et al:A role for radiotherapy in neuropathic bone pain:preliminary response rates from a prospective trial(Trans-tasman radiation oncology group, TROG 96.05). Int J Radiat Oncol Biol Phys 46:975-981, 2000
13) Loblaw DA, Laperriere NJ:Emergency treatment of malignant extradural spinal cord compression:an evidence-based guideline. J Clin Oncol 16:1613-1624, 1998
14) Helweg-Larsen S, Sorensen PS, Kreiner S:Prognostic factors in metastatic spinal cord compression:a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys 46:1163-1169, 2000
15) Klimo P, Thompson CJ, Kestle JR et al:A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol 7:64-76, 2005
16) van der Linden YM, Dijkstra SP, Vonk EJ et al:Prediction of survival in patients with metastases in the spinal column:results based on a randomized trial of radiotherapy. Cancer 103:320-328, 2005
17) Rades D, Veninga T, Stalpers LJ et al:Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol 25:50-56, 2007
18) Rades D, Fehlauer F, Schulze R et al:Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 24:3388-3393, 2006
19) Koswig S, Budach V:[Remineralization and pain relief in bone metastases after after different radiotherapy fractions(10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol 175:500-508, 1999
20) Townsend PW, Rosenthal HG, Smalley SR et al:Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol 12:2345-2350, 1994
21) 片桐浩久, 高橋満, 高木辰哉ほか:転移性骨腫瘍症例に対する治療体系-予後予測と原発巣検索-. 関節外科 22:46-54, 2003
22) 高橋健夫, 萬篤憲:骨転移. 2008放射線治療計画ガイドライン, メディカル教育研究社, 東京, 2008, pp.301-305
23) Gerszten PC, Burton SA, Welch WC et al:Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 104:2244-2254, 2005
24) 絹谷清剛:内照射療法の最近の話題:メタストロン・ゼヴァリン・甲状腺癌. 日放技会誌 65:659-667, 2009
25) 西尾正道, 佐野宗明, 玉木義雄ほか:疼痛を伴う骨転移癌患者の疼痛緩和に対する塩化ストロンチウム(Sr-89)(SMS.2P)の有用性及び安全性を評価する多施設共同オープン試験. 日医放会誌 65:399-410, 2005
26) Hird A, Chow E, Zhang L et al:Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases:results from three canadian cancer centers. Int J Radiat Oncol Biol Phys 75:193-197, 2009
P.138 掲載の参考文献
1) Tokuhashi Y, Matsuzaki H, Toriyama S et al:Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110-1013, 1990
3) Katagiri H, Takahashi M, Wakai K et al:Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698-703, 2005
4) 中馬広一:転移性脊椎腫瘍による脊髄麻痺. 新臨床腫瘍学-がん薬物療法専門医のために-改訂第2版, 南江堂, 東京, 2009, pp.797-800
5) Tomita K, Kawahara N, Baba H et al:Total en bloc spondylectomy for solitary spinal metastases. Int Orthop 18:291-298, 1994
P.145 掲載の参考文献
1) Sugiura H, Yamada K, Sugiura T et al:Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729-736, 2008
2) Fottner A, Szalantzy M, Wirthmann L et al:Bone metastases from renal cell carcinoma:patient survival after surgical treatment. BMC Musculoskelet Disord 3:145, 2010
3) Noguchi M, Kikuchi H, Ishibashi M et al:Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195-201, 2003
4) Yamashita K, Ueda T, Ono K et al:Breast cancer with bone-only metastases. Visceral metastases-free rate in relation to anatomic distribution of bone metastases. Cancer 68:634-637, 1991
5) 厚生労働省がん研究助成金「がんの骨転移に対する予後予測方法の確立と集学的治療法の開発班」編:骨転移治療ハンドブック, 金原出版, 東京, 2004
6) 転移性腫瘍 粒子線治療 兵庫県立粒子線医療センター[http://www.hibmc.shingu.hyogo.jp/prot/prot_07.html]
7) 村上昌雄, 美馬正幸, 出水祐介ほか:がん骨転移に対する原発科医と整形外科医のコンセンサス形成 転移性骨腫瘍に対する粒子線治療(会議録). 日整会誌 85:S825, 2011
8) 定位放射線治療装置「ノバリス」オフィシャルサイト[http://www.novalis.co.jp/], [http://www.accuray.com/]
9) Nakatsuka A, Yamakado K, Takaki H et al:Percutaneous radiofrequency ablation of painful spinal tumors adjacent to the spinal cord with real-time monitoring of spinal canal temperature:a prospective study. Cardiovasc Intervent Radiol 32:70-75, 2005
10) Kashima M, Yamakado K, Nakatsuka A et al:Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol 194:536-541, 2010
11) 濱田健一郎, 中西克之, 堀信一ほか:転移性骨盤部骨腫瘍に対するSAP-MS(superabsorbent polymer microsphere)を用いた経カテーテル的動脈塞栓療法. 臨整外 39:1307-1314, 2004
12) メディカルエクセレンスジャパンGate Tower Institute for Image Guided Therapy[http://www.medical-excellence-japan.org/en/hospital/006/index.html]
13) 荒木信人:転移性骨腫瘍の問題点と集学的治療の必要性. 骨・関節・靭帯 17:495-502, 2004

Part 5 がん種別骨転移治療の実際をみる

P.152 掲載の参考文献
1) 小野慈:骨シンチによる骨転移診断, 南江堂, 東京, 2003
2) Koizumi M, Yoshimoto M, Kasumi F et al:An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer 10:381, 2010
3) 日本乳癌学会編:科学的根拠に基づく乳癌診療ガイドライン 1. 治療編, 金原出版, 東京, 2011
4) Kohno N, Aogi K, Minami H et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
5) Rosen LS, Gordon D, Kaminski M et al:Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma:a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003
6) Rosen LS, Gordon DH, Dugan W Jr et al:Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43, 2004
7) Pavlakis N, Schmidt R, Stockler M:Bisphosphonates for breast cancer. Cochrane Database Syst Rev, CD003474, 2005
8) Gnant M:Zoledronic acid in the treatment of early-stage breast cancer:is there a final verdict? Curr Oncol Rep 14:35-43, 2012
9) Eidtmann H, de Boer R, Bundred N et al:Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
10) DeBoer R et al:SABCS 2010 Abstrast P5-11-01
11) Gnant M, Mlineritsch B, Schippinger W et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
12) Gnant M et al:SABCS 2010 Abstrast P5-11-02
13) Coleman RE et al:SABCS 2010 Abstrast S4-5
14) Coleman RE, Winter MC, Cameron D et al:The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response:exploratory evidence for direct anti-tumour activity in breast cancer. Brit J Cancer 102:1099-1105, 2010
15) Lin A, Park J, Melisko M et al:Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Breast Cancer Res Treat 106(suppl 1):S40, 2007(abstr 510)
16) Aft R, Naughton M, Trinkaus K et al:Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer:an open label, randomised, phase 2 trial. Lancet Oncol 11:421-428, 2010
17) Stopeck AT, Lipton A, Body JJ et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
18) Henry DH, Costa L, Goldwasser F et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma. J Clin Oncol 20:1125-1132, 2011
19) Fizazi K, Carducci M, Smith M et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011
P.158 掲載の参考文献
2) Coleman RE, Purohit OP, Vinholes JJ et al:High dose pamidronate:clinical and biochemical effects in metastatic bone disease. Cancer 80:1588-1594, 1997
3) Zekri J, Ahmed N, Coleman RE et al:The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379-382, 2001
4) 日本泌尿器科学会編:腎癌診療ガイドライン2011年版, 金原出版, 東京, 2011
5) Shinohara N, Kumagai A, Kanagawa K et al:Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol 39:720-726, 2009
6) Christodoulou C, Pervena A, Klouvas G et al:Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209-211, 2009
7) Saad F, Gleason DM, Murray R et al:Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004
8) 篠原信雄, 佐藤拓也:ビスフォスフォネートーゾレドロン酸を中心に-. Urology View 7:70-76, 2009
10) Lewington VJ, McEwan AJ, Ackery DM et al:A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27:954-958, 1991
11) Porter AT, McEwan AJ, Powe JE et al:Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993
12) Quilty PM, Kirk D, Bolger JJ et al:A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40, 1994
13) Coleman R, Cook R, Hirsh V et al:Zoledronic acid use in cancer patients:more than just supportive care? Cancer 117:11-23, 2011
14) Carroll PR, Neal D, Scher H et al:Management of disseminated prostate cancer. In:Prostate cancer:3rd International Consultation on Prostate Cancer-Paris, ed by Denis L, Bartsch G, Khoury S et al, Health Publications, Paris, 2003, pp.251-284
15) CALGB 90202. Clin Adv Hematol Oncol 4:897-898, 2006
16) Fizazi K, Carducci M, Smith M et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011
17) Neville-Webbe HL, Coleman RE:Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46:1211-1222, 2010
P.164 掲載の参考文献
2) 厚生労働省がん研究助成金 がんの骨転移に対する予後予測方法の確立と集学的治療法の開発班編:骨転移治療ハンドブック, 金原出版, 東京, 2004, pp.3-13
3) Sugiura H, Yamada K, Sugiura T et al:Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729-736, 2008
4) Tsuya A, Kurata T, Tamura K et al:Skeletal meta-stases in non-small cell lung cancer:a retrospective study. Lung Cancer 57:229-232, 2007
5) Katagiri H, Takahashi M, Inagaki J et al:Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin:a retrospective study. Cancer 86:533-537, 1999
6) 静岡県立静岡がんセンター呼吸器グループ:肺癌内科診療マニュアル EBMと静岡がんセンターの臨床から, 山本信之監修, 医薬ジャーナル社, 大阪, 2011, pp.157-179
7) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
8) Rosen LS, Gordon D, Tchekmedyian NS et al:Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621, 2004
9) 日本肺癌学会の肺癌診療ガイドライン2010年度版. [http://www.haigan.gr.jp/modules/guideline/index.php?content_id=3]
10) Hirsh V, Tchekmedyian NS, Rosen LS et al:Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors:analysis based on history of skeletal complications. Clin Lung Cancer 6:170-174, 2004
11) Hirsh V, Major PP, Lipton A et al:Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228-236, 2008
12) 日本緩和医療学会 緩和医療ガイドライン作成委員会編:がん疼痛の薬物療法に関するガイドライン2010年版, 金原出版, 東京, 2010, pp.196-197
13) Henry DH, Costa L, Goldwasser F et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
P.172 掲載の参考文献
1) 森脇昭介, 万代光一, 山上啓太郎:癌の骨髄転移の病理形態と問題点. 病理と臨床 17:28-34, 1999
2) 清水輝彦, 井口東郎:腹膜転移の診断. 臨床外科 66:1306-1311, 2011
3) Kusumoto H, Haraguchi M, Nozuka Y et al:Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer:the pathogenesis of bone destruction. Oncol Rep 16:735-740, 2006
4) 井口東郎, 横田昌樹, 澄井俊彦ほか:進行消化器癌の予後改善を目指す治療戦略 進行消化器癌における骨転移対策. 消化器科 42:161-167, 2006
5) Iguchi H, Tanaka S, Ozawa Y et al:An experimental model of bone metastasis by human lung cancer cells:the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 56:4040-4043, 1996
6) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
7) Henry DH, Costa L, Goldwasser F et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
P.178 掲載の参考文献
1) 芦原英司, 木村晋也:多発性骨髄腫に対するゾレドロン酸の臨床効果. ゾレドロン酸のEBM, メディカルレビュー社, 大阪, 2006, pp.110-122
2) 日本骨髄腫研究会編:資料2 治療の選択と治療効果. 多発性骨髄腫の診療指針 第2版, 文光堂, 東京, 2008, p73
3) Hara T, Wakatsuki S, Ozaki S et al:Primary adult T-cell leukemia/lymphoma of bone. Int J Hematol 79:157-160, 2004
4) Chiba K, Hashino S, Izumiyama K et al:Multiple osteolytic bone lesions with high serum levels of interleukin-6 and CCL chemokines in a patient with adult T cell leukemia. Int J Lab Hematol 31:368-371, 2009
5) Kumar SK, Rajkumar SV, Dispenzieri A et al:Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
6) Tsukasaki K, Utsunomiya A, Fukuda H et al:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007
7) Takasaki Y, Iwanaga M, Imaizumi Y et al:Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115:4337-4343, 2010
8) Rajikumar SV:Treatment of multiple myeloma. Nat Rev Clin Oncol 8:479-491, 2011
9) Bird JM, Owen RG, D'Sa S et al:Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32-75, 2011
10) Fukushima T, Miyazaki Y, Honda S et al:Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19:829-834, 2005
11) Hishizawa M, Kanda J, Utsunomiya A et al:Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia:a nationwide retrospective study. Blood 116:1369-1376, 2010
12) Sato K, Kimura S, Segawa H et al:Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116:94-99, 2005
13) Kato Y, Tanaka Y, Miyagawa F et al:Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J Immunol 167:5092-5098, 2001
14) Gober HJ, Kistowska M, Angman L et al:Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163-168, 2003
15) Berenson JR, Lichtenstein A, Porter L et al:Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602, 1998
16) Aviles A, Nambo MJ, Neri N et al:Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227-230, 2007
17) Morgan GJ, Davies FE, Gregory WM et al:First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controlled trial. Lancet 376:1989-1999, 2010
18) Ishikawa C, Matsuda T, Okudaira T et al:Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 136:424-432, 2007
19) Shu ST, Nadella MV, Dirksen WP et al:A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma. Cancer Res 67:11859-11866, 2007
20) Yokota A, Kimura S, Tanaka R et al:Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res 34:793-799, 2010
21) Kuroda J, Kimura S, Segawa H et al:The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102:2229-2235, 2003
22) Ruggiero SL, Mehrotra B, Rosenberg TJ et al:Osteonecrosis of the jaws associated with the use of bisphosphonates:a review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004
23) Walter C, Al-Nawas B, Grotz KA et al:Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066-1072, 2008
24) Stumpe MR, Chandra RK, Yunus F et al:Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 31:202-206, 2009
25) Badros A, Weikel D, Salama A et al:Osteonecrosis of the jaw in multiple myeloma patients:clinical features and risk factors. J Clin Oncol 24:945-952, 2006
26) Gimsing P, Carlson K, Turesson I et al:Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma(Nordic Myeloma Study Group):a double-blind, randomised controlled trial. Lancet Oncol 11:973-982, 2010
27) Vahtsevanos K, Kyrgidis A, Verrou E et al:Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362, 2009
28) Yoneda T, Hagino H, Sugimoto T et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010
29) Vij R, Horvath N, Spencer A et al:An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 84:650-656, 2009
P.184 掲載の参考文献
1) Pavlidis N, Briasoulis E, Hainsworth J et al:Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990-2005, 2003
2) Shildt RA, Kennedy PS, Chen TT et al:Management of patients with metastatic adenocarcinoma of unknown origin:a Southwest Oncology Group study. Cancer Treat Rep 67:77-79, 1983
3) Mayordomo JI, Guerra JM, Guijarro C et al:Neoplasms of unknown primary site:a clinicopathological study of autopsied patients. Tumori 79:321-324, 1993
4) Hess KR, Abbruzzese MC, Lenzi R et al:Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403-3410, 1999
5) 日本臨床腫瘍学会編:原発不明がん診療ガイドライン2010年版, メディカルレビュー社, 大阪, 2010
6) Shaw PH, Adams R, Jordan C et al:A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol(R Coll Radiol) 19:87-95, 2007
7) Destombe C, Botton E, Le Gal G et al:Investigations for bone metastasis from an unknown primary. Joint Bone Spine 74:85-89, 2007
8) Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al:Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53-58, 1977
9) Culine S:Prognostic factors in unknown primary cancer. Semin Oncol 36:60-64, 2009
10) Kodaira M, Takahashi S, Yamada S et al:Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 21:1163-1167, 2010
11) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003

Part 6 骨転移におけるBP治療の副作用対策をみる

P.190 掲載の参考文献
1) Doggrell SA:Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget's disease. Expert Rev Endocrinol Metab 4:405-415, 2009
2) Papapetrou PD:Bisphosphonate-associated adverse events. Hormones(Athens) 8:96-110, 2009
3) Markowitz GS, Fine PL, Stack JI et al:Toxic acute tubular necrosis following treatment with zoledronate(Zometa). Kidney Int 64:281-289, 2003
4) Body JJ, Pfister T, Bauss F:Preclinical perspectives on bisphosphonate renal safety. Oncologist 10(Suppl 1):3-7, 2005
6) Mehrotra B, Ruggiero S:Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 515:356-360, 2006
7) Coleman R, Burkinshaw R, Winter M et al:Zoledronic acid. Expert Opin Drug Saf 10:133-145, 2011
8) Durie BG, Kyle RA, Belch A et al:Myeloma management guidelines:a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4:379-389, 2003
9) 有馬聡, 白木良一, 星長清隆ほか:維持透析中の進行性腎癌骨転移例に対しゾレドロン酸を投与した2症例の検討. 日泌会誌 99:660-665, 2008
P.197 掲載の参考文献
2) Marx RE:Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg 61:1115-1117, 2003
3) Yoneda T, Hagino H, Sugimoto T et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010
4) 米田俊之, 萩野浩, 杉本利嗣ほか:ビスフォスフォネートの有用性と顎骨壊死, 大阪大学出版会, 大阪, 2010, pp.1-128
5) Ruggiero SL, Dodson TB, Assael LA et al:American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 67(5 Suppl):2-12, 2009
6) Fizazi K, Carducci M, Smith M et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011
7) Cheung A, Seeman E:Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473-2474, 2010
8) Urade M, Tanaka N, Furusawa K et al:Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69:e364-e371, 2011

Part 7 骨転移治療の今後を展望する

P.204 掲載の参考文献
1) Fleisch H:Bisphosphonates in bone disease. From the laboratory to the Patient., 3rd edition, The Parthenon Publishing Group Inc., New York, 1997
2) Luckman SP, Hughes DE, Coxon FP et al:Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 7:581-589, 1998
3) Senaratne SG, Pirianov G, Mansi JL et al:Bisphos-phonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468, 2000
4) Denoyelle C, Hong L, Vannier JP et al:New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects. Br J Cancer 88:1631-1640, 2003
5) Ottewell PD, Monkkonen H, Jones M et al:Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178, 2008
6) Santini D, Martini F, Fratto ME et al:In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31-38, 2009
7) Fournier P, Boissier S, Filleur S et al:Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544, 2002
8) Green J, Clezardin P:The molecular basis of bis-phosphonate activity:a preclinical perspective. Semin Oncol 37(Suppl 1):S3-S11, 2010
9) Morgan GJ, Davies FE, Gregory WM et al:First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controlled trial. Lancet 376:1989-1999, 2010
10) Gnant M, Mlineritsch B, Schippinger W et al:Endocrine therapy plus zoledronic acid in premeno-pausal breast cancer. N Engl J Med 360:679-691, 2009
11) Gnant M, Eidtmann H:The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more... Crit Rev Oncol Hematol 74(Suppl 1):S2-S6, 2010
12) Coleman RE, Winter MC, Cameron D et al:The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response:exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105, 2010
13) Coleman RE, Marshall H, Cameron D et al:Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
14) Aft R, Naughton M, Trinkaus K et al:Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer:an open label, randomised, phase 2 trial. Lancet Oncol 11:421-428, 2010
P.212 掲載の参考文献
1) Schramek D, Leibbrandt A, Sigl V et al:Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102, 2010
2) Gonzalez-Suarez E, Jacob AP, Jones J et al:RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107, 2010
3) Schramek D, Sigl V, Penninger JM:RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188-194, 2011
4) Jones DH, Nakashima T, Sanchez OH et al:Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696, 2006
5) Tan W, Zhang W, Strasner A et al:Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548-553, 2011
6) Body JJ, Facon T, Coleman RE et al:A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228, 2006
7) Yonemori K, Fujiwara Y, Minami H et al:Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 99:1237-1242, 2008
8) Stopeck AT, Lipton A, Body JJ et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
9) Van Poznak CH, Temin S, Yee GC et al:American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
10) Fizazi K, Carducci M, Smith M et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011
11) Vij R, Horvath N, Spencer A et al:An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 84:650-656, 2009
12) Yasuda Y, Kaleta J, Bromme D:The role of cathepsins in osteoporosis and arthritis:rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993, 2005
13) Jensen AB, Wynne C, Ramirez G et al:The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases:results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 10:452-458, 2010
14) Soriano P, Montgomery C, Geske R et al:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991
15) Marzia M, Sims NA, Voit S et al:Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320, 2000
16) Saad F, Lipton A:SRC kinase inhibition:targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36:177-184, 2010
17) Yu EY, Wilding G, Posadas E et al:Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428, 2009
18) Lara PN Jr, Longmate J, Evans CP et al:A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer:a California Cancer Consortium study. Anticancer Drugs 20:179-184, 2009
19) Takahashi S, Miyazaki M, Okamoto I et al:Phase I study of dasatinib(BMS-354825)in Japanese patients with solid tumors. Cancer Sci 102:2058-2064, 2011
20) Felding-Habermann B:Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203-213, 2003
21) Nakamura I, Duong le T, Rodan SB et al:Involvement of αvβ3 integrins in osteoclast function. J Bone Miner Metab 25:337-344, 2007
22) Rosenthal MA, Davidson P, Rolland F et al:Evaluation of the safety, pharmacokinetics and treatment effects of an αvβ3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 6:42-48, 2010
23) Ozaki S, Tanaka O, Fujii S et al:Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86:180-185, 2007
24) Mukherjee S, Raje N, Schoonmaker JA et al:Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504, 2008
25) Qiang YW, Hu B, Chen Y et al:Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319-4330, 2009
26) Padmanabhan S:A phase I/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma(MM)patients treated with zoledronic acid(Zol)and anti-myeloma therapy(MM Tx). ASH #750, 2009(abstr)
27) Edwards CM, Edwards JR, Lwin ST et al:Increasing Wnt signaling in the bone marrow micro-environment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833-2842, 2008
29) Moester MJ, Papapoulos SE, Lowik CW et al:Sclerostin:current knowledge and future perspectives. Calcif Tissue Int 87:99-107, 2010
30) Terpos E, Christoulas D, Katodritou E et al:Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma:reduction post-bortezomib monotherapy. Int J Cancer, 2011(in printing)
31) Padhi D, Jang G, Stouch B et al:Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011
32) Vallet S, Mukherjee S, Vaghela N et al:Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 107:5124-5129, 2010
33) Terpos E:Elevated levels of circulating activin-A correlate with features of advanced disease, extensive bone involvement and inferior survival in patients with multiple myeloma. ASH #2967, 2010(abstr)
34) Bagnato A, Loizidou M, Pflug BR et al:Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163:220-233, 2011
35) Guise TA, Yin JJ, Mohammad KS:Role of endothelin-1 in osteoblastic bone metastases. Cancer 97:779-784, 2003
36) Nelson JB, Nabulsi AA, Vogelzang NJ et al:Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-1149, 2003
37) James ND, Caty A, Payne H et al:Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan(ZD4054)in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain:a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106:966-973, 2010

Part 8 骨転移治療 advanced lecture Q & A

P.217 掲載の参考文献
1) Morote J, Martinez E, Trilla E et al:Osteoporosis during continuous androgen deprivation:influence of the modality and length of treatment. Eur Urol 44:661-665, 2003
2) Saad F, Eastham J:Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175-1181, 2010
3) Carroll PR, Neal D, Scher H et al:Management of disseminated prostate cancer. In:Prostate cancer:3rd International Consultation on Prostate Cancer-Paris, ed by Denis L, Bartsch G, Khoury S et al, Health Publications, Paris, 2003, pp.251-284
4) CALGB 90202. Clin Adv Hematol Oncol 4:897-898, 2006
5) Woodward E, Jagdev S, McParland L et al:Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160-166, 2011
7) Van Poznak CH, Temin S, Yee GC et al:American Society of Ciinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
8) Terpos E, Sezer O, Croucher PI et al:The use of bisphosphonates in multiple myeloma:recommen-dations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303-1317, 2009
P.221 掲載の参考文献
大森浩之監修, 副島林造ほか編:骨転移-病態・診断・治療, 金芳堂, 京都, 1995
P.225 掲載の参考文献
1) Wedin R, Bauer HC:Surgical treatment of skeletal metastatic lesions of the proximal femur:endoprosthesis or reconstruction nail? J Bone Joint Surg Br 87:1653-1657, 2005
2) Rompe JD, Eysel P, Hopf C et al:Metastatic instability at the proximal end of the femur. Comparison of endoprosthetic replacement and plate osteosynthesis. Arch Orthop Trauma Surg 113:260-264, 1994
3) Harada H, Katagiri H, Kamata M et al:Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res(Tokyo) 51:131-136, 2010
P.228 掲載の参考文献
1) Hillner BE, Ingle JN, Chlebowski RT et al:American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
2) 中原理紀, 藤井博史, 久保敦司:骨転移痛治療の新たな展開 骨転移痛に対する放射性同位元素(89Sr)の役割. 緩和医療学 7:393-401, 2005
3) Storto G, Klain M, Paone G et al:Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35-41, 2006
P.231 掲載の参考文献
1) Yuasa T, Kimura S, Ashihara E et al:Zoledronic acid-a multiplicity of anti-cancer action-. Curr Med Chem 14:2126-2135, 2007
2) Narita N, Yuasa T, Tsuchiya N et al:A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer 8:224, 2008
3) Weilbaecher KN, Guise TA, McCauley LK:Cancer to bone:a fatal attraction. Nat Rev Cancer 11:411-425, 2011
4) Clines GA, Guise TA:Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 6:e7, 2008
5) Coleman RE, Major P, Lipton A et al:Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005
6) Yuasa T, Maita S, Tsuchiya N et al:Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75:1131-1137, 2010
7) Jung K, Miller K, Wirth M et al:Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 59:604-612, 2011
P.233 掲載の参考文献
1) Chemy NI:The assessment of cancer pain. In:Textbook of pain, 5th ed, ed by McMahon S, Koltzenburg M, Churchill Livingstone, Philadelphia, 2006, pp.1099-1125
2) de Courcy JG:Interventional techniques for cancer pain management. Clin Oncol(R Coll Radiol) 23:407-417, 2011
3) 関山裕詩, 齋藤勇一郎, 山田芳嗣:骨転移痛に対する神経ブロック療法の適応とコツ. ペインクリニック 29:736-742, 2008
4) 細川豊史:神経ブロック. がん疼痛の薬物療法に関するガイドライン<2010年版>, 日本緩和医療学会緩和医療ガイドライン作成委員会編, 金原出版, 東京, 2010, pp.88-96
P.236 掲載の参考文献
1) Van Poznak CH, Temin S, Yee GC et al:American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
3) Koizumi M, Yonese J, Fukui I et al:Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167:1863-1866, 2002
4) Lein M, Wirth M, Miller K et al:Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52:1381-1387, 2007
5) Brown JE, Cook RJ, Major P et al:Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
6) Lipton A, Cook R, Saad F et al:Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201, 2008
7) Coleman RE, Major P, Lipton A et al:Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005
8) Leeming DJ, Koizumi M, Byrjalsen I et al:The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32-38, 2006
9) Chung YC, Ku CH, Chao TY et al:Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 15:424-428, 2006
10) Koizumi M, Takahashi S, Ogata E:Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23:4095-4100, 2003

最近チェックした商品履歴

Loading...